# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2022 Earnings Results

**Report date:** 2023-02-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2022

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.25%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $12.56 | N/A | +53.62% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in the company's performance and future prospects. They highlighted their commitment to innovation and product development.

**Key quotes:**

> We are pleased with our strong EPS performance this quarter.

> Our focus remains on innovation and expanding our product pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and possibly strong sales of its products. The stock's 4.25% increase reflects investor optimism following the earnings report. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2022_